If you are one of those who pop painkillers all too often, then you might be raising your risk of heart attack and heart ...

resulting in low potential drug–drug interactions. When given as an intravenous bolus, immediate and full platelet inhibition of ADP-induced platelet aggregation was observed. The clinical ...

Human platelet lysates (HPL) are abundant in bioactive factors, and numerous studies have demonstrated their beneficial effects on neurological diseases, including their anti-neuroinflammatory ability ...

Platelets and basophils (different myeloid cells responsible ... The main treatment for CML is targeted cancer drugs (such as tyrosine kinase inhibitors). Other possible treatments include ...

Exclusive agreement to acquire Nudge Therapeutics includes their series of cGAS inhibitors. Nudge has developed novel potent ... by the U.S. Food and Drug Administration and has been awarded Orphan ...

IPA: Inhibition of platelet aggregation ... The combined use of antiplatelet drugs acting through different mechanisms is important in antithrombotic treatment of patients with cardiovascular ...

Opdivo is part of a class of drugs called PD-1 inhibitors, which enhance the immune system's ability to fight cancer by removing its natural brakes. Like other PD-1 drugs such as Merck's (MRK.N ...

All COX2 inhibitors undergo oxidative drug metabolism by cytochrome P450 ... 50 is not only a potent inhibitor of platelet aggregation, but also interferes with processes leading to hypertension ...

There was an inverse J-shaped association between HbA1c categories and dispensing of these drugs with the strongest association in patients with a HbA1c between 8 and 9% (OR 1.42, 1.39–1.46 for SGLT2i ...